347 related articles for article (PubMed ID: 32336421)
1. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
2. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F
Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ; Wilson NR; Pemmaraju N
Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
[TBL] [Abstract][Full Text] [Related]
6. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
8. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
9. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
10. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
11. CD123 as a Therapeutic Target Against Malignant Stem Cells.
Sugita M; Guzman ML
Hematol Oncol Clin North Am; 2020 Jun; 34(3):553-564. PubMed ID: 32336419
[TBL] [Abstract][Full Text] [Related]
12. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.
Testa U; Pelosi E; Castelli G
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547472
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
14. Blastic Plasmacytoid Dendritic Cell Neoplasm in Children.
Li Y; Sun V; Sun W; Pawlowska A
Hematol Oncol Clin North Am; 2020 Jun; 34(3):601-612. PubMed ID: 32336423
[TBL] [Abstract][Full Text] [Related]
15. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
Pelosi E; Castelli G; Testa U
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kharfan-Dabaja MA; Cherry M
Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
[TBL] [Abstract][Full Text] [Related]
17. CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia.
Shi M; Su RJ; Parmar KP; Chaudhry R; Sun K; Rao J; Chen M
Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):195-204. PubMed ID: 31244444
[TBL] [Abstract][Full Text] [Related]
18. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
[TBL] [Abstract][Full Text] [Related]
19. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
